MX2022010977A - Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos. - Google Patents

Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos.

Info

Publication number
MX2022010977A
MX2022010977A MX2022010977A MX2022010977A MX2022010977A MX 2022010977 A MX2022010977 A MX 2022010977A MX 2022010977 A MX2022010977 A MX 2022010977A MX 2022010977 A MX2022010977 A MX 2022010977A MX 2022010977 A MX2022010977 A MX 2022010977A
Authority
MX
Mexico
Prior art keywords
braf
kras
egfr
targets
inhibitors
Prior art date
Application number
MX2022010977A
Other languages
English (en)
Inventor
Alexander BRIDGES
Mukesh K Nyati
Jason Christopher Rech
Brennan Taylor Watch
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of MX2022010977A publication Critical patent/MX2022010977A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En el presente documento se proporcionan compuestos que son útiles en el tratamiento del cáncer.
MX2022010977A 2020-03-05 2021-03-05 Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos. MX2022010977A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062985561P 2020-03-05 2020-03-05
PCT/US2021/020990 WO2021178741A1 (en) 2020-03-05 2021-03-05 Inhibitors of egfr, kras, braf, and other targets and use of the same

Publications (1)

Publication Number Publication Date
MX2022010977A true MX2022010977A (es) 2022-12-02

Family

ID=77612748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010977A MX2022010977A (es) 2020-03-05 2021-03-05 Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos.

Country Status (11)

Country Link
US (1) US20230098205A1 (es)
EP (1) EP4114386A4 (es)
JP (1) JP2023515689A (es)
KR (1) KR20220150358A (es)
CN (1) CN115768423A (es)
AU (1) AU2021230553A1 (es)
BR (1) BR112022017724A2 (es)
CA (1) CA3174538A1 (es)
IL (1) IL296091A (es)
MX (1) MX2022010977A (es)
WO (1) WO2021178741A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
WO2020055761A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN113164418A (zh) 2018-12-05 2021-07-23 米拉蒂治疗股份有限公司 组合疗法
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2022056307A1 (en) 2020-09-11 2022-03-17 Mirati Therapeutics, Inc. Crystalline forms of a kras g12c inhibitor
WO2022132200A1 (en) 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
CN119899194B (zh) * 2025-03-31 2025-06-24 浙江省人民医院 双环杂芳基类braf负变构调节剂及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547977A (en) * 1967-10-27 1970-12-15 Velsicol Chemical Corp Novel carbanilates
GB0701955D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
WO2014176475A2 (en) * 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof
CA3091834A1 (en) * 2018-02-23 2019-08-29 The Regents Of The University Of Michigan Egfr dimer disruptors and use of the same

Also Published As

Publication number Publication date
EP4114386A1 (en) 2023-01-11
JP2023515689A (ja) 2023-04-13
US20230098205A1 (en) 2023-03-30
AU2021230553A1 (en) 2022-10-13
CN115768423A (zh) 2023-03-07
CA3174538A1 (en) 2021-09-10
IL296091A (en) 2022-11-01
WO2021178741A1 (en) 2021-09-10
KR20220150358A (ko) 2022-11-10
BR112022017724A2 (pt) 2022-10-18
EP4114386A4 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
MX2022010977A (es) Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos.
MX2022010975A (es) Inhibidores de egfr, kras, braf y otras dianas y uso de estos.
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2024009727A (es) Terapias de combinacion.
ZA202202559B (en) Kras g12c inhibitors and methods of using the same
WO2020050890A3 (en) Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
MX2025001648A (es) Inhibidores del oncogen homologo del virus de sarcoma de rata kirsten (kras)
PH12020551923A1 (en) Methods and compositions for treating cancer
EP4268898A3 (en) Kras g12c inhibitors for treating cancer
MX2021005700A (es) Inhibidores de kras g12c y metodos de uso de los mismos.
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
MX2020010836A (es) Inhibidores de kras g12c y métodos para su uso.
MX2020011582A (es) Inhibidores de kras g12c y metodos para su uso.
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
MX2020002502A (es) Inhibidores de kras g12c y metodos para utilizarlos.
WO2022031952A3 (en) Treatments for cancers having kras mutations
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2025008674A (es) Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
MX2023002104A (es) Composiciones y métodos para tratar cánceres positivos para egfr.
MX2025007378A (es) Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2
WO2021102359A3 (en) Taspase1 inhibitors and uses thereof